PT85086B - Processo para a preparacao de composicoes farmaceuticas para supositorios contendo n-ciclo-propil-metil-7alfa-{(s)-1-hidroxi-1,2,2-trimetil-propil /-6,14-endo--etano-6,7,8,14-tetra-hidro-nororipavina - Google Patents
Processo para a preparacao de composicoes farmaceuticas para supositorios contendo n-ciclo-propil-metil-7alfa-{(s)-1-hidroxi-1,2,2-trimetil-propil /-6,14-endo--etano-6,7,8,14-tetra-hidro-nororipavina Download PDFInfo
- Publication number
- PT85086B PT85086B PT85086A PT8508687A PT85086B PT 85086 B PT85086 B PT 85086B PT 85086 A PT85086 A PT 85086A PT 8508687 A PT8508687 A PT 8508687A PT 85086 B PT85086 B PT 85086B
- Authority
- PT
- Portugal
- Prior art keywords
- glycol
- weight
- propyl
- suppository
- administration
- Prior art date
Links
- 239000000829 suppository Substances 0.000 claims abstract description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 27
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 241000792859 Enema Species 0.000 claims 2
- 239000007920 enema Substances 0.000 claims 2
- 229940095399 enema Drugs 0.000 claims 2
- 241000132536 Cirsium Species 0.000 claims 1
- 235000014443 Pyrus communis Nutrition 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 abstract description 12
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 230000007794 irritation Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000007792 addition Methods 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 3
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 3
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 3
- 238000013138 pruning Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 241001441754 Heteralocha acutirostris Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000042115 Propylea Species 0.000 description 1
- 241000167589 Rangia Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/15—Suppositories
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61141086A JPS62298530A (ja) | 1986-06-16 | 1986-06-16 | 坐薬用医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT85086A PT85086A (en) | 1987-07-01 |
| PT85086B true PT85086B (pt) | 1990-03-08 |
Family
ID=15283879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT85086A PT85086B (pt) | 1986-06-16 | 1987-06-16 | Processo para a preparacao de composicoes farmaceuticas para supositorios contendo n-ciclo-propil-metil-7alfa-{(s)-1-hidroxi-1,2,2-trimetil-propil /-6,14-endo--etano-6,7,8,14-tetra-hidro-nororipavina |
Country Status (10)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3432689A (en) * | 1988-03-24 | 1989-10-16 | Bukh Meditec A/S | Controlled release composition |
| US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| JP2007016052A (ja) * | 1998-03-03 | 2007-01-25 | Eisai R & D Management Co Ltd | 抗痴呆薬を含有した経皮適用製剤又は坐剤 |
| US7413748B2 (en) * | 2002-12-13 | 2008-08-19 | Purdue Pharma L.P. | Transdermal buprenorphine to treat pain in sickle cell crisis |
| US7135436B2 (en) * | 2003-05-05 | 2006-11-14 | J.F. Daley International, Ltd. | Solid algicide, preparation and usage in recirculating water |
| US9415034B2 (en) * | 2005-01-05 | 2016-08-16 | National Defense Medical Center | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP2907524A1 (en) | 2007-05-25 | 2015-08-19 | RB Pharmaceuticals Limited | Sustained delivery formulations of risperidone compounds |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| WO2018165183A1 (en) * | 2017-03-06 | 2018-09-13 | Tactus Therapeutics, Inc. | Abuse deterrent opioid formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870061A (en) * | 1956-11-08 | 1959-01-20 | Mead Johnson & Co | Concentrates of dialkyl sulfosuccinates |
| US3474101A (en) * | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| DE2229770A1 (de) * | 1972-06-19 | 1974-01-10 | Boehringer Sohn Ingelheim | N-(heteroarylmethyl)-7alpha-acyl6,14-endoaethenotetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung |
| US4004010A (en) * | 1972-06-19 | 1977-01-18 | Boehringer Ingelheim Gmbh | Pharmaceutical compositions containing an N-(furyl-methyl)-7α-acyl-6,14-(endoetheno or endoethano)-tetrahydro-nororipavine or -northebaine and method of use |
| DE2230154A1 (de) * | 1972-06-21 | 1974-01-17 | Boehringer Sohn Ingelheim | N-(heteroaryl-methyl)-6,14-endoaetheno7alpha-hydroxyalkyl-tetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung |
| JPS54157820A (en) * | 1978-05-30 | 1979-12-13 | Res Inst For Prod Dev | Preparation of multi-layered suppository base |
| US4486412A (en) * | 1983-03-15 | 1984-12-04 | Pharmacaps, Inc. | Encapsulated antacid dispersions |
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| US4699776A (en) * | 1985-06-28 | 1987-10-13 | R. P. Scherer Corporation | Suppositories containing analgesics, antipyretics or anti-inflammatory agents |
-
1986
- 1986-06-16 JP JP61141086A patent/JPS62298530A/ja active Granted
-
1987
- 1987-06-08 IE IE152287A patent/IE59668B1/en not_active IP Right Cessation
- 1987-06-15 CA CA000539723A patent/CA1283605C/en not_active Expired - Lifetime
- 1987-06-15 US US07/061,973 patent/US4784855A/en not_active Expired - Lifetime
- 1987-06-16 PT PT85086A patent/PT85086B/pt unknown
- 1987-06-16 EP EP87108631A patent/EP0253143B1/en not_active Expired - Lifetime
- 1987-06-16 AT AT87108631T patent/ATE67932T1/de not_active IP Right Cessation
- 1987-06-16 ES ES198787108631T patent/ES2039377T3/es not_active Expired - Lifetime
- 1987-06-16 DK DK305087A patent/DK167559B1/da not_active IP Right Cessation
- 1987-06-16 DE DE8787108631T patent/DE3773440D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2039377T3 (es) | 1993-10-01 |
| ATE67932T1 (de) | 1991-10-15 |
| EP0253143B1 (en) | 1991-10-02 |
| DK167559B1 (da) | 1993-11-22 |
| CA1283605C (en) | 1991-04-30 |
| DE3773440D1 (de) | 1991-11-07 |
| JPS62298530A (ja) | 1987-12-25 |
| IE59668B1 (en) | 1994-03-09 |
| IE871522L (en) | 1987-12-16 |
| JPH0475889B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-12-02 |
| DK305087D0 (da) | 1987-06-16 |
| EP0253143A3 (en) | 1989-08-23 |
| US4784855A (en) | 1988-11-15 |
| DK305087A (da) | 1987-12-17 |
| PT85086A (en) | 1987-07-01 |
| EP0253143A2 (en) | 1988-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT85086B (pt) | Processo para a preparacao de composicoes farmaceuticas para supositorios contendo n-ciclo-propil-metil-7alfa-{(s)-1-hidroxi-1,2,2-trimetil-propil /-6,14-endo--etano-6,7,8,14-tetra-hidro-nororipavina | |
| CN102198126B (zh) | 治疗口腔及牙齿疾病的涂抹剂及其涂抹器 | |
| US6299902B1 (en) | Enhanced transdermal anesthesia of local anesthetic agents | |
| ES2241198T3 (es) | Preparacion aplicable percutaneamente que contiene hidrocloruro de donepezil. | |
| Wöhler | The treatment of haemochromatosis with desferrioxamine | |
| ES2611351T3 (es) | Formulación para tratamiento tópico de heridas | |
| EP0480054A1 (en) | Percutaneously absorbable composition of morphine hydrochloride | |
| Zhao et al. | Ascidian‐inspired temperature‐switchable hydrogels with antioxidant fullerenols for protecting radiation‐induced oral mucositis and maintaining the homeostasis of oral microbiota | |
| EP2566488A2 (en) | Povidone-iodine topical composition | |
| JPS5823630A (ja) | 薬剤禁断症状の処置剤 | |
| EA022847B1 (ru) | Дезинфицирующий и антисептический препарат, имеющий сниженное содержание йода | |
| Lionel et al. | Levamisole in the treatment of ascariasis in children | |
| JP2669951B2 (ja) | 麻薬性鎮痛剤を含有する経皮吸収組成物 | |
| Gosselin et al. | Trends in the therapy of acute poisonings | |
| US4289783A (en) | Etomidate-containing compositions | |
| CN108619142B (zh) | 一种长效复方氟苯尼考注射液及其制备方法 | |
| JPH0563452B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP0106812A2 (en) | Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction | |
| JPH03120230A (ja) | 薬効成分の経皮吸収促進剤及び経皮吸収型製剤 | |
| JPS6483024A (en) | Cataplasm for cold | |
| JPH044300B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS61200918A (ja) | 外用消炎鎮痛剤 | |
| CA2387953C (en) | Compositions for electroporation | |
| HUP0003528A2 (hu) | Dihidropoliprenolokat tartalmazó gyógyászati készítmények | |
| JP7253328B2 (ja) | 外用医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC3A | Transfer or assignment |
Free format text: 971015 RECKITT & COLMAN PRODUCTS LIMITED GB |
|
| PD3A | Change of proprietorship |